Trial Profile
An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Torasemide (Primary) ; Furosemide
- Indications Natriuresis
- Focus Therapeutic Use
- Sponsors Sarfez Pharmaceuticals
- 18 Jan 2020 Planned End Date changed from 30 Jun 2019 to 30 Jun 2022.
- 18 Jan 2020 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2022.
- 18 Jan 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 17 Jul 2018 to 30 Jun 2021.